



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

PCT/EP03/09145

REC'D 10 NOV 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02102170.4

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



PCT/EP03 / 09145

Anmeldung Nr:
Application no.: 02102170.4
Demande no:

Anmeldetag:
Date of filing: 19.08.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DSM N.V.
Het Overloon 1
6411 TE Heerlen
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

NOVEL BAKING ENZYME NBE 030 AND USES THEREOF

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12N9/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

NOVEL BAKING ENZYME NBE 030 AND USES THEREOF

5

Field of the invention

The invention relates to a newly identified polynucleotide sequence comprising a gene that encodes a novel baking enzyme. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel baking enzyme as well as the amino acid sequence of the full-length functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a baking enzyme according to the invention is genetically modified to enhance its activity and/or level of expression.

Background of the invention

20

Baked products such as bread are prepared from a dough which is usually made from the basic ingredients (wheat) flour, water and optionally salt. Depending on the baked products, other ingredients added may be are sugars, flavours etceteras. For leavened products, primarily baker's yeast is used next to chemical leavening systems such as a combination of an acid (generating compound) and bicarbonate.

25

In order to improve the handling properties of the dough and/or the final properties of the baked products there is a continuous effort to develop processing aids with improving properties. Processing aids are defined herein as compounds that improve the handling properties of the dough and/or the final properties of the baked products. Dough properties that may be improved comprise machineability, gas retaining capability, reduced stickiness, elasticity, extensibility, moldability etcetera. Properties of the baked products that may be improved comprise loaf volume, crust crispiness, crumb texture and softness, flavour relative staleness and shelf life. These dough and/or baked product improving processing aids can be divided into two groups: chemical additives and enzymes.

30
35

Yeast, enzymes and chemical additives are generally added separately to the dough. Yeast may be added as a liquid suspension, in a compressed form or as

active dry (ADY) or instant dry yeast (IDY). The difference between these yeast formulations is the water- and yeast dry matter content. Liquid yeast has a yeast dry matter content of less than 25% (w/v). Cream yeast is a particular form of liquid yeast and has a dry matter content between 17 and 23% (w/v). Compressed yeast has a dry matter content between 25-35% (w/v) while the dry yeast formulations have a dry matter content between 92-98% (w/v).

Enzymes may be added in a dry, e.g. granulated form or in dissolved form. The chemical additives are in most cases added in powder form. Also, processing aid compositions which are tailored to specific baking applications, may be composed of a dedicated mixture of chemical additives and enzyme.

The preparation of a dough from the ingredients and processing aids described above is well known in the art and comprises mixing of said ingredients and processing aids and one or more moulding and fermentation steps.

The preparation of baked products from such doughs is also well known in the art and may comprise molding and shaping and further fermentation of the dough followed by baking at required temperatures and baking times.

Chemical additives with improving properties comprise oxidising agents such as ascorbic acid, bromate and azodicarbonate, reducing agents such as L-cysteine and glutathione, emulsifiers acting as dough conditioners such as diacetyl tartaric esters of mono/diglycerides (DATEM), sodium stearoyl lactylate (SSL) or calcium stearoyl lactylate (CSL), or acting as crumb softeners such as glycerol monostearate (GMS) etceteras, fatty materials such as triglycerides (fat) or lecithin and others.

As a result of a consumer-driven need to replace the chemical additives by more natural products, several enzymes have been developed with dough and/or baked product improving properties and which are used in all possible combinations depending on the specific baking application conditions. Suitable enzymes include starch degrading enzymes, arabinoxylan- and other hemicellulose degrading enzymes, cellulose degrading enzymes, oxidizing enzymes, fatty material splitting enzymes, protein degrading, modifying or crosslinking enzymes.

Starch degrading enzymes are for instance endo-acting enzymes such as alpha-amylase, maltogenic amylase, pullulanase or other debranching enzymes and exo-acting enzymes that cleave off glucose (amyloglucosidase), maltose (beta-amylase), maltotriose, maltotetraose and higher oligosaccharides.

Arabinoxylan- and other hemicellulose degrading enzymes are for instance xylanases, pentosanases, hemicellulase, arabinofuranosidase, glucanase and

others.

Cellulose degrading enzymes are for instance cellulase (beta-1,4-endoglucanase), cellobiohydrolase and beta-glucosidase.

5 Oxidizing enzymes are for instance glucose oxidase, hexose oxidase, pyranose oxidase, sulfhydryl oxidase, lipoxygenase, laccase, polyphenol oxidases and others.

Fatty material splitting enzymes are for instance triacylglycerol lipases, phospholipases (such as A₁, A₂, B, C and D) and galactolipases.

10 Protein degrading, modifying or crosslinking enzymes are for instance endo-acting proteases (serine proteases, metalloproteases, aspartyl proteases, thiol proteases), exo-acting peptidases that cleave off one amino acid, or dipeptide, tripeptide etceteras from the N-terminal (aminopeptidases) or C-terminal (carboxypeptidases) ends of the polypeptide chain, asparagines or glutamine deamidating enzymes such as

15 deamidase and peptidoglutaminase or crosslinking enzymes such as transglutaminase. Baking enzymes may conveniently be produced in microorganisms. Microbial baking enzymes are available from a variety of sources; Bacillus spec. are a common source of bacterial enzymes, whereas fungal enzymes are commonly produced in Aspergillus spec.

20 Baking enzymes may be used in a manifold of baked goods. The term "baked goods" is herein defined as to comprise bread products such as tin bread, loaves of bread, French bread as well as rolls, cakes, pies, muffins, yeast raised and cake doughnuts and the like.

25 In the above processes, it is advantageous to use baking enzymes that are obtained by recombinant DNA techniques. Such recombinant enzymes have a number of advantages over their traditionally purified counterparts. Recombinant enzymes may be produced at a low cost price, high yield, free from contaminating agents like bacteria or viruses but also free from bacterial toxins or contaminating other enzyme activities.

Object of the invention

30

It is an object of the invention to provide novel polynucleotides encoding novel baking enzymes with improved properties. A further object is to provide naturally and recombinantly produced baking enzymes as well as recombinant strains producing these. Also fusion polypeptides are part of the invention as well as
35 methods of making and using the polynucleotides and polypeptides according to the invention.

Summary of the invention

The invention provides for novel polynucleotides encoding novel baking enzymes, in particular enzymes with Triacylglycerol lipase activity (E.C. Number 3.1.1.3).

More in particular, the invention provides for polynucleotides having a nucleotide sequence that hybridises preferably under highly stringent conditions to a sequence according to SEQ ID NO: 1 or SEQ ID NO: 2. Consequently, the invention provides nucleic acids that are more than 40% such as about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homologous to the sequences according to SEQ ID NO: 1 or SEQ ID NO: 2.

In a more preferred embodiment the invention provides for such an isolated polynucleotide obtainable from a filamentous fungus, in particular *A. niger* is preferred.

In one embodiment, the invention provides for an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide with an amino acid sequence as shown in SEQ ID NO: 3 or functional equivalents thereof.

In a further preferred embodiment, the invention provides an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

In a preferred embodiment the invention provides a baking enzyme gene according to SEQ ID NO: 1. In another aspect the invention provides a polynucleotide, preferably a cDNA encoding an *A. niger* baking enzyme whose amino acid sequence is shown in SEQ ID NO: 3 or variants or fragments of that polypeptide. In a preferred embodiment the cDNA has a sequence according to SEQ ID NO: 2 or functional equivalents thereof.

In an even further preferred embodiment, the invention provides for a polynucleotide comprising the coding sequence of the polynucleotides according to the invention, preferred is the polynucleotide sequence of SEQ ID NO: 2.

The invention also relates to vectors comprising a polynucleotide sequence according to the invention and primers, probes and fragments that may be used to amplify or detect the DNA according to the invention.

In a further preferred embodiment, a vector is provided wherein the polynucleotide sequence according to the invention is functionally linked with regulatory sequences suitable for expression of the encoded amino acid sequence in a suitable

host cell, such as *A. niger* or *A. oryzae*. The invention also provides methods for preparing polynucleotides and vectors according to the invention.

The invention also relates to recombinantly produced host cells that contain heterologous or homologous polynucleotides according to the invention.

5 In another embodiment, the invention provides recombinant host cells wherein the expression of a baking enzyme according to the invention is significantly increased or wherein the activity of the baking enzyme is increased.

10 In another embodiment the invention provides for a recombinantly produced host cell that contains heterologous or homologous DNA according to the invention and wherein the cell is capable of producing a functional baking enzyme according to the invention, preferably a cell capable of over-expressing the baking enzyme according to the invention, for example an *Aspergillus* strain comprising an increased copy number of a gene or cDNA according to the invention.

15 In yet another aspect of the invention, a purified polypeptide is provided. The polypeptides according to the invention include the polypeptides encoded by the polynucleotides according to the invention. Especially preferred is a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.

20 Accordingly, in one aspect the present invention provides a baking enzyme composition containing as an active ingredient an enzyme according to SEQ ID NO: 3 or functional equivalents thereof.

In another aspect, the invention provides a method of making baked goods wherein there is incorporated into the dough used for making the baked goods an enzyme according to SEQ ID NO: 3 or functional equivalents thereof.

25 Fusion proteins comprising a polypeptide according to the invention are also within the scope of the invention. The invention also provides methods of making the polypeptides according to the invention.

The invention also relates to the use of the baking enzyme according to the invention in any industrial process as described herein

30 **Detailed description of the invention**

Polynucleotides

35 The present invention provides polynucleotides encoding a baking enzyme, tentatively called NBE 030, having an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof. The sequence of the gene encoding NBE

030 was determined by sequencing a genomic clone obtained from *Aspergillus niger*. The invention provides polynucleotide sequences comprising the gene encoding the NBE 030 baking enzyme as well as its complete cDNA sequence and its coding sequence. Accordingly, the invention relates to an isolated polynucleotide comprising
5 the nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof.

More in particular, the invention relates to an isolated polynucleotide hybridisable under stringent conditions, preferably under highly stringent conditions, to a polynucleotide according to SEQ ID NO: 1 or SEQ ID NO: 2. Advantageously, such
10 polynucleotides may be obtained from filamentous fungi, in particular from *Aspergillus niger*. More specifically, the invention relates to an isolated polynucleotide having a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2.

The invention also relates to an isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional
15 equivalents thereof.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which may be isolated from chromosomal DNA, which include an open reading frame encoding a protein, e.g. an *A. niger* baking enzyme. A gene may include coding sequences, non-coding sequences, introns and regulatory
20 sequences. Moreover, a gene refers to an isolated nucleic acid molecule as defined herein.

A nucleic acid molecule of the present invention, such as a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or a functional equivalent thereof, can be isolated using standard molecular biology
25 techniques and the sequence information provided herein. For example, using all or portion of the nucleic acid sequence of SEQ ID NO: 1 or the nucleotide sequence of SEQ ID NO: 2 as a hybridization probe, nucleic acid molecules according to the invention can be isolated using standard hybridization and cloning techniques (e. g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A*
30 *Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1 or SEQ ID NO: 2 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence
35 information contained in SEQ ID NO:1 or SEQ ID NO: 2.

A nucleic acid of the invention can be amplified using cDNA, mRNA

or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

Furthermore, oligonucleotides corresponding to or hybridisable to
5 nucleotide sequences according to the invention can be prepared by standard synthetic techniques, e. g., using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 2. The sequence of SEQ ID NO: 2 corresponds to the coding region of the A. niger NBE 030 cDNA. This
10 cDNA comprises sequences encoding the A. niger NBE 030 polypeptide according to SEQ ID NO: 3.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or a functional
15 equivalent of these nucleotide sequences.

A nucleic acid molecule which is complementary to another nucleotide sequence is one which is sufficiently complementary to the other nucleotide sequence such that it can hybridize to the other nucleotide sequence thereby forming a stable duplex.

20 One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a functional equivalent thereof such as a biologically active fragment or domain, as well as nucleic acid molecules sufficient for use as hybridisation probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for
25 use as PCR primers for the amplification or mutation of nucleic acid molecules.

An "isolated polynucleotide" or "isolated nucleic acid" is a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment,
30 an isolated nucleic acid includes some or all of the 5' non-coding (e.g., promotor) sequences that are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a
35 genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a

hybrid gene encoding an additional polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

As used herein, the terms "polynucleotide" or "nucleic acid molecule" are intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The nucleic acid may be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to an NBE 030 nucleic acid molecule, e.g., the coding strand of an NBE 030 nucleic acid molecule. Also included within the scope of the invention are the complement strands of the nucleic acid molecules described herein.

Sequencing errors

20

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular *A. niger* which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.

25

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion

35

in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.

Nucleic acid fragments, probes and primers

A nucleic acid molecule according to the invention may comprise only a portion or a fragment of the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2, for example a fragment which can be used as a probe or primer or a fragment encoding a portion of a NBE 030 protein. The nucleotide sequence determined from the cloning of the NBE 030 gene and cDNA allows for the generation of probes and primers designed for use in identifying and/or cloning other NBE 030 family members, as well as NBE 030 homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide which typically comprises a region of nucleotide sequence that hybridizes preferably under highly stringent conditions to at least about 12 or 15, preferably about 18 or 20, preferably about 22 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 or more consecutive nucleotides of a nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO: 2 or of a functional equivalent thereof.

Probes based on the NBE 030 nucleotide sequences can be used to detect transcripts or genomic NBE 030 sequences encoding the same or homologous proteins for instance in other organisms. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such probes can also be used as part of a diagnostic test kit for identifying cells which express a NBE 030 protein.

Identity & homology

The terms "homology" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the

sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two sequences are the same length.

The skilled person will be aware of the fact that several different computer programmes are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity two amino acid or nucleotide sequence is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at: <http://vega.igh.cnrs.fr/bin/align-guess.cgi>) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with

the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to NBE 030 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to NBE 030 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Hybridisation

As used herein, the term "hybridizing" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 50%, at least about 60%, at least about 70%, more preferably at least about 80%, even more preferably at least about 85% to 90%, more preferably at least 95% homologous to each other typically remain hybridized to each other.

A preferred, non-limiting example of such hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45 °C, followed by one or more washes in 1 X SSC, 0.1 % SDS at 50 °C, preferably at 55 °C, preferably at 60 °C and even more preferably at 65 °C.

Highly stringent conditions include, for example, hybridizing at 68 °C in 5x SSC/5x Denhardt's solution / 1.0% SDS and washing in 0.2x SSC/0.1% SDS at room temperature. Alternatively, washing may be performed at 42 °C.

The skilled artisan will know which conditions to apply for stringent and highly stringent hybridisation conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) tract of mRNAs), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-standed cDNA clone).

Obtaining full length DNA from other organisms

5 In a typical approach, cDNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species *Aspergillus* can be screened.

For example, *Aspergillus* strains can be screened for homologous NBE 030 polynucleotides by Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, cDNA libraries can be
10 constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using a probe hybridisable to a NBE 030 polynucleotide according to the invention.

Homologous gene sequences can be isolated, for example, by
15 performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.

The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and
20 sequenced to ensure that the amplified sequences represent the sequences of a new NBE 030 nucleic acid sequence, or a functional equivalent thereof.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the
25 labeled fragment can be used to screen a genomic library.

PCR technology also can be used to isolate full length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse
transcription reaction can be performed on the RNA using an oligonucleotide primer
30 specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C
35 primer). Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook et al., supra; and

Ausubel et al., supra.

Whether or not a homologous DNA fragment encodes a functional NBE 030 protein, may easily be tested by methods known in the art. Methods for testing enzyme activity of Triacylglycerol lipase s (E.C. number 3.1.1.3) may be found on <http://www.biochem.ucl.ac.uk/bsm/enzymes/>.

Vectors

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NBE 030 protein or a functional equivalent thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms "plasmid" and "vector" can be used interchangeably herein as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operatively linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the

host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signal). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in a certain host cell (e.g. tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein (e.g. NBE 030 proteins, mutant forms of NBE 030 proteins, fragments, variants or functional equivalents thereof, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NBE 030 proteins in prokaryotic or eukaryotic cells. For example, NBE 030 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episome, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled person. In a specific embodiment, promoters are preferred that are capable of directing a high expression level of baking enzymes in filamentous fungi. Such promoters are known in the art. The expression constructs may contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the

mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, transduction, infection, lipofection, cationic lipid-mediated transfection or
10 electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2nd, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Davis et al., *Basic Methods in Molecular Biology* (1986) and other laboratory manuals.

15 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
20 Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a NBE 030 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. cells that have incorporated the
25 selectable marker gene will survive, while the other cells die).

Expression of proteins in prokaryotes is often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, e.g. to the amino terminus of the recombinant protein. Such
30 fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the
35 recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa,

thrombin and enterokinase.

As indicated, the expression vectors will preferably contain selectable markers. Such markers include dihydrofolate reductase or neomycin resistance for eukarotic cell culture and tetracycline or ampicillin resistance for culturing in *E. coli* and other bacteria. Representative examples of appropriate host include bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera Sf9*; animal cells such as CHO, COS and Bowes melanoma; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16A, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are PWLNEO, pSV2CAT, pOG44, pZT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters for use in the present invention include *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signal may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional

heterologous functional regions: Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, peptide moieties may be added to the

5 polypeptide to facilitate purification.

Polypeptides according to the invention

The invention provides an isolated polypeptide having the amino acid

10 sequence according to SEQ ID NO: 3, an amino acid sequence obtainable by expressing the polynucleotide of SEQ ID NO: 1 in an appropriate host, as well as an amino acid sequence obtainable by expressing the polynucleotide sequences of SEQ ID NO: 2 in an appropriate host. Also, a peptide or polypeptide comprising a functional equivalent of the above polypeptides is comprised within the present invention. The

15 above polypeptides are collectively comprised in the term "polypeptides according to the invention"

The terms "peptide" and "oligopeptide" are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids coupled by peptidyl

20 linkages. The word "polypeptide" is used herein for chains containing more than seven amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus. The one-letter code of amino acids used herein is commonly known in the art and can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2nd, ed.

25 *Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)

By "isolated" polypeptide or protein is intended a polypeptide or protein removed from its native environment. For example, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the

30 purpose of the invention as are native or recombinant polypeptides which have been substantially purified by any suitable technique such as, for example, the single-step purification method disclosed in Smith and Johnson, *Gene* 67:31-40 (1988).

The NBE 030 baking enzyme according to the invention can be recovered and purified from recombinant cell cultures by well-known methods including

35 ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction

chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

5 Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of
10 the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

A NBE 030 polypeptide according to the invention may be advantageously used in baking processes. The amount of enzyme to be added to the dough is determined empirically. It may depend on the quality of the flour used, the
15 degree of improvement which is required, the kind of bread or baked goods, the method of preparing the dough, the proportion of other ingredients etcetera.

The effect of the addition of the NBE 030 enzyme according to the invention manifests itself in the physical properties of dough and the quality of the baked goods. By the addition of the enzyme, the dough has improved elasticity, is less
20 sticky, and machinability is significantly improved. Also, the volume of the baked goods is increased, the crumb has a finer structure and a better softness is obtained. Staling of the bread is suppressed when a NBE 030 enzyme is added to the dough.

Protein fragments

25

The invention also features biologically active fragments of the polypeptides according to the invention.

Biologically active fragments of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from
30 the amino acid sequence of the NBE 030 protein (e.g., the amino acid sequence of SEQ ID NO: 3), which include fewer amino acids than the full length protein, and exhibit at least one biological activity of the corresponding full-length protein. Typically, biologically active fragments comprise a domain or motif with at least one activity of the NBE 030 protein. Preferred is a fragment with Triacylglycerol lipase activity.

35

A biologically active fragment of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the biological activities of the native form of a polypeptide of the invention.

The invention also features nucleic acid fragments which encode the
5 above biologically active fragments of the NBE 030 protein.

Fusion proteins

The proteins of the present invention or functional equivalents
10 thereof, e.g., biologically active portions thereof, can be operatively linked to a non-NBE 030 polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. As used herein, a NBE 030 "chimeric protein" or "fusion protein" comprises a NBE 030 polypeptide operatively linked to a non-NBE 030 polypeptide. A "NBE 030 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to
15 NBE 030, whereas a "non-NBE 030 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the NBE 030 protein, e.g., a protein which is different from the NBE 030 protein and which is derived from the same or a different organism. Within a NBE 030 fusion protein the NBE 030 polypeptide can correspond to all or a portion of a NBE 030
20 protein. In a preferred embodiment, a NBE 030 fusion protein comprises at least one biologically active fragment of a NBE 030 protein. In another preferred embodiment, a NBE 030 fusion protein comprises at least two biologically active portions of a NBE 030 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the NBE 030 polypeptide and the non-NBE 030 polypeptide are fused in-frame to
25 each other. The non-NBE 030 polypeptide can be fused to the N-terminus or C-terminus of the NBE 030 polypeptide.

For example, in one embodiment, the fusion protein is a GST-NBE
030 fusion protein in which the NBE 030 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant NBE
30 030. In another embodiment, the fusion protein is a NBE 030 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian and Yeast host cells), expression and/or secretion of NBE 030 can be increased through use of a heterologous signal sequence.

In another example, the gp67 secretory sequence of the baculovirus
35 envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of

eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

A signal sequence can be used to facilitate secretion and isolation of a protein or polypeptide of the invention. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain. Thus, for instance, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide, which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gents et al, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The HA tag is another peptide useful for purification which corresponds to an epitope derived of influenza hemagglutinin protein, which has been described by Wilson et al., *Cell* 37:767 (1984), for instance.

Preferably, a NBE 030 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two

consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g, a GST polypeptide). A NBE 030-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NBE 030 protein.

Functional equivalents

The terms "functional equivalents" and "functional variants" are used interchangeably herein. Functional equivalents of NBE 030 DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the NBE 030 *A. niger* baking enzyme as defined herein. A functional equivalent of a NBE 030 polypeptide according to the invention is a polypeptide that exhibits at least one function of an *A. niger* baking enzyme as defined herein. Functional equivalents therefore also encompass biologically active fragments.

Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino acids of SEQ ID NO: 3 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a non-essential amino acid is a residue that can be altered in SEQ ID NO: 3 without substantially altering the biological function. For example, amino acid residues that are conserved among the NBE 030 proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, amino acids conserved among the NBE 030 proteins according to the present invention and other baking enzymes are not likely to be amenable to alteration.

The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (e.g.lysine, arginine and hystidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagines, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine tryptophan, histidine).

Functional nucleic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide.

Accordingly, the invention provides nucleic acid molecules encoding NBE 030 proteins that contain changes in amino acid residues that are not essential for a particular biological activity. Such NBE 030 proteins differ in amino acid sequence from SEQ ID NO: 3 yet retain at least one biological activity. In one embodiment the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J.U. et al., Science 247:1306-1310 (1990) wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selects or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al, supra, and the references cited therein.

An isolated nucleic acid molecule encoding a NBE 030 protein homologous to the protein according to SEQ ID NO: 3 can be created by introducing one or more nucleotide substitutions, additions or deletions into the coding nucleotide sequences according to SEQ ID NO: 1 or SEQ ID NO: 2 such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein. Such mutations may be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.

The term "functional equivalents" also encompasses orthologues of the A. niger NBE 030 protein. Orthologues of the A. niger NBE 030 protein are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID NO: 3.

As defined herein, the term "substantially homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number

of identical or equivalent (e.g., with similar side chain) amino acids or nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain. For example, amino acid or nucleotide sequences which contain a common domain having about 60%, preferably
5 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.

Also, nucleic acids encoding other NBE 030 family members, which thus have a nucleotide sequence that differs from SEQ ID NO: 1 or SEQ ID NO: 2, are within the scope of the invention. Moreover, nucleic acids encoding NBE 030 proteins
10 from different species which thus have a nucleotide sequence which differs from SEQ ID NO: 1 or SEQ ID NO: 2 are within the scope of the invention.

Nucleic acid molecules corresponding to variants (e.g. natural allelic variants) and homologues of the NBE 030 DNA of the invention can be isolated based on their homology to the NBE 030 nucleic acids disclosed herein using the cDNAs
15 disclosed herein or a suitable fragment thereof, as a hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions.

In addition to naturally occurring allelic variants of the NBE 030 sequence, the skilled person will recognise that changes can be introduced by mutation
20 into the nucleotide sequences of SEQ ID NO: 1 or SEQ ID NO: 2 thereby leading to changes in the amino acid sequence of the NBE 030 protein without substantially altering the function of the NBE 030 protein.

In another aspect of the invention, improved NBE 030 proteins are provided. Improved NBE 030 proteins are proteins wherein at least one biological
25 activity is improved. Such proteins may be obtained by randomly introducing mutations along all or part of the NBE 030 coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological activity. For instance, the art provides for standard assays for measuring the enzymatic activity of baking enzymes and thus improved proteins may easily be selected.

30 In a preferred embodiment the NBE 030 protein has an amino acid sequence according to SEQ ID NO: 3. In another embodiment, the NBE 030 polypeptide is substantially homologous to the amino acid sequence according to SEQ ID NO: 3 and retains at least one biological activity of a polypeptide according to SEQ ID NO: 3, yet differs in amino acid sequence due to natural variation or mutagenesis as
35 described above.

In a further preferred embodiment, the NBE 030 protein has an amino

acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a nucleic acid according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably under highly stringent hybridisation conditions.

Accordingly, the NBE 030 protein is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 and retains at least one functional activity of the polypeptide according to SEQ ID NO: 3.

Functional equivalents of a protein according to the invention can also be identified e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for baking enzyme activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods that can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations of truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used

techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan. (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).

In addition to the NBE 030 gene sequence shown in SEQ ID NO: 1, it will be apparent for the person skilled in the art that DNA sequence polymorphisms that may lead to changes in the amino acid sequence of the NBE 030 protein may exist within a given population. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.

Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding functional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having a NBE 030 activity include, inter alia, (1) isolating the gene encoding the NBE 030 protein, or allelic variants thereof from a cDNA library e.g. from other organisms than *A. niger*; (2) in situ hybridization (e.g. FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the NBE 030 gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for detecting expression of NBE 030 mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the NBE 030 probe in a given biological (e.g. tissue) sample.

Also encompassed by the invention is a method of obtaining a functional equivalent of a NBE 030 gene or cDNA. Such a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence according to SEQ ID NO: 3 or a variant thereof; screening a nucleic acid

fragment library with the labelled probe under conditions that allow hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the NBE 030 gene.

5 In one embodiment, a NBE 030 nucleic acid of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nucleic acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or the complement thereof.

10 In another preferred embodiment a NBE 030 polypeptide of the invention is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

Host cells

15 In another embodiment, the invention features cells, e.g., transformed host cells or recombinant host cells that contain a nucleic acid encompassed by the invention. A "transformed cell" or "recombinant cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a
20 nucleic acid according to the invention. Both prokaryotic and eukaryotic cells are included, e.g., bacteria, fungi, yeast, and the like, especially preferred are cells from filamentous fungi, in particular *Aspergillus niger*.

 A host cell can be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired
25 fashion. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may facilitate optimal functioning of the protein.

 Various host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products.
Appropriate cell lines or host systems familiar to those of skill in the art of molecular
30 biology and/or microbiology can be chosen to ensure the desired and correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such host cells are well known in the art.

35 Host cells also include, but are not limited to, mammalian cell lines such as CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and choroid plexus

cell lines.

If desired, the polypeptides according to the invention can be produced by a stably-transfected cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, methods for constructing
5 such cell lines are also publicly known, e.g., in Ausubel et al. (supra).

Antibodies

The invention further features antibodies, such as monoclonal or
10 polyclonal antibodies, that specifically bind NBE 030 proteins according to the invention.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to NBE
15 030 protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any of a
20 variety of methods. For example, cells expressing the NBE 030 protein or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of NBE 030 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal
25 antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or NBE 030 protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., *Nature* 256:495 (1975); Kohler et al., *Eur. J. Immunol.* 6:511 (1976); Hammerling et al.,
30 In: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with a NBE 030 protein antigen or, with a NBE 030 protein expressing cell. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however,
35 it is preferably to employ the parent myeloma cell line (SP₂O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting

hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastro-enterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the NBE 030 protein antigen. In general, the polypeptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., supra, mixed with an adjuvant, and injected into a host mammal.

In particular, various host animals can be immunized by injection of a polypeptide of interest. Examples of suitable host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), adjuvant mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridomas producing the mAbs of this invention can be cultivated *in vitro* or *in vivo*.

Once produced, polyclonal or monoclonal antibodies are tested for specific recognition of a NBE 030 polypeptide or functional equivalent thereof in an immunoassay, such as a Western blot or immunoprecipitation analysis using standard techniques, e.g., as described in Ausubel et al., supra. Antibodies that specifically bind to NBE 030 proteins or functional equivalents thereof are useful in the invention. For example, such antibodies can be used in an immunoassay to detect NBE 030 in pathogenic or non-pathogenic strains of *Aspergillus* (e.g., in *Aspergillus* extracts).

Preferably, antibodies of the invention are produced using fragments of the NBE 030 polypeptides that appear likely to be antigenic, by criteria such as high frequency of charged residues. For example, such fragments may be generated by standard techniques of PCR, and then cloned into the pGEX expression vector (Ausubel et al., supra). Fusion proteins may then be expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., supra. If desired, several (e.g., two or three) fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, typically including at least three booster injections. Typically, the antisera are checked for their ability to immunoprecipitate a recombinant NBE 030 polypeptide or functional equivalents thereof whereas unrelated proteins may serve as

a control for the specificity of the immune reaction.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against a NBE 030 polypeptide or functional equivalents thereof. Kits for generating and screening phage display libraries are commercially available e.g. from Pharmacia.

Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223, 409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 20791; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Polyclonal and monoclonal antibodies that specifically bind NBE 030 polypeptides of functional equivalents thereof can be used, for example, to detect expression of a NBE 030 gene or a functional equivalent thereof e.g. in another strain of *Aspergillus*. For example, NBE 030 polypeptide can be readily detected in conventional immunoassays of *Aspergillus* cells or extracts. Examples of suitable assays include, without limitation, Western blotting, ELISAs, radioimmune assays, and the like.

By "specifically binds" is meant that an antibody recognizes and binds a particular antigen, e.g., a NBE 030 polypeptide, but does not substantially recognize and bind other unrelated molecules in a sample.

Antibodies can be purified, for example, by affinity chromatography methods in which the polypeptide antigen is immobilized on a resin.

An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in cells or tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen or in the diagnosis of Aspergillosis..

Detection can be facilitated by coupling the antibody to a detectable

substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable
5 fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include ^{125}I , ^{131}I , ^{35}S or ^3H .

10 Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Hydrophobicity plots of the proteins of the invention can be used to identify hydrophilic regions.

The antigenic peptide of a protein of the invention comprises at least
15 7 (preferably 10, 15, 20, or 30) contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 3 and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are
20 regions of NBE 030 that are located on the surface of the protein, e.g., hydrophilic regions, hydrophobic regions, alpha regions, beta regions, coil regions, turn regions and flexible regions.

Immunoassays

25 Qualitative or quantitative determination of a polypeptide according to the present invention in a biological sample can occur using any art-known method. Antibody-based techniques provide special advantages for assaying specific polypeptide levels in a biological sample.

In these, the specific recognition is provided by the primary antibody
30 (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunocomplex is obtained.

Accordingly, the invention provides a method for diagnosing whether a certain organism is infected with *Aspergillus* comprising the steps of:

- 35
- Isolating a biological sample from said organism suspected to be infected with *Aspergillus*,

- reacting said biological sample with an antibody according to the invention,
- determining whether immune complexes are formed.

Tissues can also be extracted, e.g., with urea and neutral detergent, for the liberation of protein for Western-blot or dot/slot assay. This technique can also
5 be applied to body fluids.

Other antibody-based methods useful for detecting NBE 030 gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, NBE 030-specific monoclonal antibodies can be used both as an immunoabsorbent and as an enzyme-labeled probe
10 to detect and quantify the NBE 030 protein. The amount of NBE 030 protein present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. In another ELISA assay, two distinct specific monoclonal antibodies can be used to detect NBE 030 protein in a biological fluid. In this assay, one of the antibodies is used as the immuno-absorbent
15 and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting NBE 030 protein with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the
20 labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample.

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate.
25 Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labelled antibody/substrate reaction.

Besides enzymes, other suitable labels include radioisotopes, such as iodine (^{125}I , ^{127}I), carbon (^{14}C), sulphur (^{35}S), tritium (^3H), indium (^{112}In), and
30 technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Specific binding of a test compound to a NBE 030 polypeptide can be detected, for example, in vitro by reversibly or irreversibly immobilizing the NBE 030 polypeptide on a substrate, e.g., the surface of a well of a 96-well polystyrene microtitre
35 plate. Methods for immobilizing polypeptides and other small molecules are well known

in the art. For example, the microtitre plates can be coated with a NBE 030 polypeptide by adding the polypeptide in a solution (typically, at a concentration of 0.05 to 1 mg/ml in a volume of 1-100 ul) to each well, and incubating the plates at room temperature to 37 °C for 0.1 to 36 hours. Polypeptides that are not bound to the plate can be removed
5 by shaking the excess solution from the plate, and then washing the plate (once or repeatedly) with water or a buffer. Typically, the polypeptide is contained in water or a buffer. The plate is then washed with a buffer that lacks the bound polypeptide. To block the free protein-binding sites on the plates, the plates are blocked with a protein that is unrelated to the bound polypeptide. For example, 300 ul of bovine serum
10 albumin (BSA) at a concentration of 2 mg/ml in Tris-HCl is suitable. Suitable substrates include those substrates that contain a defined cross-linking chemistry (e.g., plastic substrates, such as polystyrene, styrene, or polypropylene substrates from Corning Costar Corp. (Cambridge, MA), for example) . If desired, a beaded particle, e.g., beaded agarose or beaded sepharose, can be used as the substrate.

15 Binding of the test compound to the polypeptides according to the invention can be detected by any of a variety of artknown methods. For example, a specific antibody can be used in an immunoassay. If desired, the antibody can be labeled (e.g., fluorescently or with a radioisotope) and detected directly (see, e.g., West and McMahon, J. Cell Biol. 74:264, 1977). Alternatively, a second antibody can be
20 used for detection (e.g., a labeled antibody that binds the Fc portion of an anti-AN97 antibody). In an alternative detection method, the NBE 030 polypeptide is labeled, and the label is detected (e.g., by labeling a NBE 030 polypeptide with a radioisotope, fluorophore, chromophore, or the like). In still another method, the NBE 030 polypeptide is produced as a fusion protein with a protein that can be detected
25 optically, e.g., green fluorescent protein (which can be detected under UV light). In an alternative method, the NBE 030 polypeptide can be covalently attached to or fused with an enzyme having a detectable enzymatic activity, such as horse radish peroxidase, alkaline phosphatase, a-galactosidase, or glucose oxidase. Genes encoding all of these enzymes have been cloned and are readily available for use by
30 those of skill in the art. If desired, the fusion protein can include an antigen, and such an antigen can be detected and measured with a polyclonal or monoclonal antibody using conventional methods. Suitable antigens include enzymes (e.g., horse radish peroxidase, alkaline phosphatase, and a-galactosidase) and non-enzymatic polypeptides (e.g., serum proteins, such as BSA and globulins, and milk proteins, such
35 as caseins).

Epitopes, antigens and immunogens.

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of
5 this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic
10 epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen, H. M. et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind),
15 it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. et al., Science 219:660-666 (1984). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical
20 rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, soluble peptides, especially those containing proline residues, usually are effective. Sutcliffe et al., supra,
25 at 661. For instance, 18 of 20 peptides designed according to these guidelines, containing 8-39 residues covering 75% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.

30 Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the native protein. Sutcliffe et
35 al., supra, at 663. The antibodies raised by antigenic epitope bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different

peptides may be used for tracking the fate of various regions of a protein precursor which undergoes posttranslation processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (e.g., about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson, I.A. et al., Cell 37:767-778 at 777 (1984). The anti-peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods well known in the art.

Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are considered epitope-bearing peptides or polypeptides of the invention and also are useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided); and sequences containing proline residues are particularly preferred.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, a short epitope-bearing amino acid sequence may be fused to a larger polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies.

Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment of the HAI polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four weeks. Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further

described in U.S. Patent No. 4,631,211 to Houghten et al. (1986). In this procedure the individual resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods.

5 A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously. Houghten et al., *supra*, at 5134.

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow, M. et al., *Proc. Natl. Acad. Sci. USA* 10 82:910-914; and Bittle, F.J. et al., *J. Gen. Virol.* 66:2347-2354 (1985).

Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using a linker 15 such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde.

Animals such as rabbits, rats and mice are immunized with either free or carriercoupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 ug peptide or carrier protein and Freund's adjuvant. 20 Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid 25 support and elution of the selected antibodies according to methods well known in the art.

Immunogenic epitope-bearing peptides of the invention, i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance, 30 Geysen et al., 1984, *supra*, discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one 35 of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen et al. with a

resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the entire 213 amino acid sequence of the protein. Then, a complete replacement set of peptides in which all 20 amino acids were substituted in turn at every position within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further describes this method of identifying a peptide bearing an immunogenic epitope of a desired protein.

Further still, U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. et al. (1996) on Peralkylated Oligopeptide Mixtures discloses linear C1-C7-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.

Use of NBE 030 baking enzymes in Industrial processes

The invention also relates to the use of the NBE 030 baking enzyme according to the invention in a selected number of industrial processes. Despite the long term experience obtained with these processes, the baking enzyme according to the invention features a number of significant advantages over the enzymes currently used. Depending on the specific application, these advantages can include aspects like lower production costs, higher specificity towards the substrate, less antigenic, less undesirable side activities, higher yields when produced in a suitable microorganism, more suitable pH and temperature ranges, better tastes of the final product as well as food grade and kosher aspects.

CLAIMS

1. An isolated polynucleotide hybridisable to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2.
- 5 2. An isolated polynucleotide according to claim 1 hybridisable under high stringency conditions to a polynucleotide according to SEQ ID NO:1 or SEQ ID NO: 2.
3. An isolated polynucleotide according to claims 1 or 2 obtainable from a filamentous fungus.
- 10 4. An isolated polynucleotide according to claim 3 obtainable from *A. niger*.
5. An isolated polynucleotide encoding a polypeptide comprising an amino acid sequence according to SEQ ID NO: 3 or functional equivalents thereof.
6. An isolated polynucleotide encoding at least one functional domain of a polypeptide according to SEQ ID NO: 3 or functional equivalents thereof.
- 15 7. An isolated polynucleotide comprising a nucleotide sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or functional equivalents thereof.
8. An isolated polynucleotide according to SEQ ID NO: 1 or SEQ ID NO: 2.
9. A vector comprising a polynucleotide sequence according to claims 1 to 8.
10. A vector according to claim 9 wherein said polynucleotide sequence according to claims 1 to 8 is operatively linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.
- 20 11. A vector according to claim 10 wherein said suitable host cell is a filamentous fungus.
12. A method for manufacturing a polynucleotide according to claims 1 – 8 or a vector according to claims 9 to 11 comprising the steps of culturing a host cell transformed with said polynucleotide or said vector and isolating said polynucleotide or said vector from said host cell.
- 25 13. An isolated polypeptide according to SEQ ID NO: 3 or functional equivalents

thereof.

14. An isolated polypeptide according to claim 13 obtainable from *Aspergillus niger*.
- 5 15. An isolated polypeptide obtainable by expressing a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11 in an appropriate host cell, e.g. *Aspergillus niger*.
16. Recombinant baking enzyme comprising a functional domain of a NBE 030 polypeptide.
- 10 17. A method for manufacturing a polypeptide according to claims 13 to 16 comprising the steps of transforming a suitable host cell with an isolated polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11, culturing said cell under conditions allowing expression of said polynucleotide and optionally purifying the encoded polypeptide from said cell or culture medium.
- 15 18. A recombinant host cell comprising a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11.
19. A recombinant host cell expressing a polypeptide according to claims 13 to 16.
20. Purified antibodies reactive with a polypeptide according to claims 13 to 16.
21. Fusion protein comprising a polypeptide sequence according to claims 13 to 16.

ABSTRACT

The invention relates to a newly identified polynucleotide sequence :
comprising a gene that encodes a novel baking enzyme. The invention features the full
length nucleotide sequence of the novel gene, the cDNA sequence comprising the full
5 length coding sequence of the novel baking enzyme as well as the amino acid
sequence of the full-length functional protein and functional equivalents thereof. The
invention also relates to methods of using these enzymes in industrial processes and
methods of diagnosing fungal infections. Also included in the invention are cells
transformed with a polynucleotide according to the invention and cells wherein a baking
10 enzyme according to the invention is genetically modified to enhance its activity and/or
level of expression.

SEQUENCE LISTING

<110> DSM N.V.

<120> Novel baking enzyme, NBE030, and uses thereof

<130> 21080EP/P0/

<160> 3

<170> XML to WIPO ST.25 Converter - <http://www.biomax.de/>

<210> 1

<211> 2769

<212> DNA

<213> *Aspergillus niger*

<400> 1

gtgaacaatg	attagacttg	gagaacgtgg	tctcogattg	gaagtggact	atctatttaa	60
tagtattgcc	aaggctttct	gatcggcaaa	catattgtcc	tcccgtgggtg	actggtttct	120
cgootgatgt	gaatagtgat	tatcaattta	taccottcgt	cagcactgat	tgaataagaa	180
cttacctcac	attgccctca	tttctatgct	ggaaccatgc	acctatTTTT	aagccatccg	240
gccgatctta	ctcacggtat	gggctgactt	tgtatcacaa	cccatacctg	tcgaccgtct	300
aaagtggggt	cagtgacaag	catgatgccg	gtcagcatca	tcagctcaac	aaattctagc	360
caacaacgga	gatcagtggg	ccgacatttg	atgtagaatt	aaaccgcgac	acgtcggaat	420
ggcttcattc	tcgggtcttag	tttcccaatc	gaagctgggt	cagcgcccag	acgcggagcg	480
tgggggtggg	accccggtatt	ttccccaca	accttggctg	tggttggcac	tttttcatta	540
gcctccatcc	tgtgcgcaga	tactagagaa	ctctacatca	tgccatcgag	gtttgttagt	600
tagatttggt	aactagctga	gcggtgtagg	tgcattgcgt	acggtgagtt	tgtctatctt	660
ttgtatagcc	ggaagccgaa	ggtaccccgc	gtcatggcta	tataaggctt	gtatatccca	720
tgctctggtg	gatgggacaa	caagaacggc	gatccgatag	aatcatgggtg	caggggtgtg	780
cttttggtg	gctcgggtcg	gctgcctctg	ctttgggcac	ttatgcgccc	tactacgcga	840
atttgacatg	ggagcaacca	cggactctgt	ccaactggtc	caaccttacc	gtcgagacac	900
ggacagggac	gttcattggg	atgctcaatg	acaacttacc	agacgttcga	cagtttctgc	960
gagttcctta	tgccaaggta	attctctcgc	tgtacacatg	tcatactgtg	tctgacatga	1020
ccagcctcct	attggggatt	taagatggct	tcctcctcat	cggcttgaca	actcaagcag	1080
aacatatgac	tccaccttct	atggcccagg	taagtagtct	tccatacaac	tatgagcagt	1140
tccaattaac	ccgagttcag	cctgtccgca	gtatgttcca	gcagagagcg	atTTTTggaa	1200
tgaatatgaa	ccggagaatt	tgctgctcaa	tgtcggcgaa	aggctcaacc	agggctctac	1260
ggcatgggtc	tcgtcagagg	attgcctgtc	cctagcggta	tggactccat	cgtatgctaa	1320
tgagacatcc	aagctgccag	ttgcgctggt	tgtcacggga	ggtggtggca	tcacaggggg	1380
tatcaacatt	ccgtcccagc	tgccctctgc	ttgggtatct	cgctctcagg	agcatatcgt	1440
tgttaccatc	aattaccgog	tcaatatTTT	tggcagtaag	tatttgctct	atatttgcaa	1500
atattagcct	gacatgtata	gatcccaa	cgcgtgcgtt	gaatgatacg	tcgcttacgc	1560
tgatggacgt	gcgcgctgct	gtggagtggg	tatatgagaa	cattgaagcg	ttcgggtggt	1620
atcccgaaaa	tattatgggtc	agactacaag	tttctctca	catgactaga	gctaacagta	1680
agcagctatg	gggacagtca	caaggtgctt	tgttgacgca	tctgtacacc	ctcgcatggc	1740
cagaagagcc	tcttgccgcc	aagttcggcg	tcatctccca	aggagcatct	gccacactca	1800
acctctctac	cacgcccgat	gtgtaccaag	actttgacat	cgtggccaag	ggactaggct	1860
gcaattatgg	tgatgatgcc	gaggccgagc	tggagtgc	gcgtgggatt	tcctgggtgc	1920
agatcgagga	gtatatcaac	cgctacaata	gctctccttc	tattgctttc	acgaactata	1980
ttcgtatgta	cccatcttgc	tcttttaact	gcccctaact	acaatatcag	ccgatgagaa	2040
atacatcttc	tccgacgaaa	gacagcggtta	ccttgagcgg	aaggttgccc	gaggcccgtc	2100
aattcgatct	gacacggcgc	gagaattccc	tagcacaaac	acgacctcag	taaataattga	2160
agaaggcgaa	tcagactgtc	tggcagtgac	tgaccttgcg	ctacgtgcgt	ccattgggct	2220
cgagacctat	cgctactact	gggctgggtat	gtccaatgac	tttccatact	gaagatagtg	2280

ctaacataaa	caggcaactt	ctccaatata	agtcocgtac	cgtggctagg	agcattccac	2340
tggaccgacc	tgctgatgat	cttcggtacg	tataatctgg	acgtcggcga	gatctcgcag	2400
ttggaagtcg	acacctctgc	cacgatgcaa	gattatctac	tcgcctttct	gaaggactca	2460
tcaaccgtca	gcgagacggt	cggatggccg	ttatatctgg	gcaacgagac	caacggagga	2520
ctcatcctgg	agttcggtaa	cggcacagca	gtgcggacca	tcacaggtga	ctggctcgac	2580
gcgggatgtt	tcaattcatc	tatcccattc	agaatctggg	ggtagcctat	acacaccatc	2640
atcagagtag	tatatacatc	atatccacaa	atccatctcc	acctatatac	ataaacccca	2700
actgaatcta	caacagcgcc	tggtccttct	ccccctcccc	ctctttaatt	tccctcgcc	2760
tctcccat						2769

<210> 2

<211> 1623

<212> DNA

<213> *Aspergillus niger*

<220>

<221> CDS

<222> (1)..(1623)

<400> 2

atg	gtg	cag	ggt	gtg	gct	ttt	gga	ctg	ctc	ggg	ctg	gct	gcc	tct	gct	48
Met	Val	Gln	Gly	Val	Ala	Phe	Gly	Leu	Leu	Gly	Leu	Ala	Ala	Ser	Ala	
1			5					10					15			
ttg	ggc	act	tat	gcg	ccc	tac	tac	gcg	aat	ttg	aca	tgg	gag	caa	cca	96
Leu	Gly	Thr	Tyr	Ala	Pro	Tyr	Tyr	Ala	Asn	Leu	Thr	Trp	Glu	Gln	Pro	
			20					25					30			
cgg	act	ctg	tcc	aac	tgg	tcc	aac	ctt	acc	gtc	gag	aca	cgg	aca	ggg	144
Arg	Thr	Leu	Ser	Asn	Trp	Ser	Asn	Leu	Thr	Val	Glu	Thr	Arg	Thr	Gly	
			35				40					45				
acg	ttc	att	ggt	atg	ctc	aat	gac	act	tac	cca	gac	ggt	cga	cag	ttt	192
Thr	Phe	Ile	Gly	Met	Leu	Asn	Asp	Thr	Tyr	Pro	Asp	Val	Arg	Gln	Phe	
	50					55					60					
ctg	cga	gtt	cct	tat	gcc	aag	cct	cct	att	ggg	gat	tta	aga	tgg	ctt	240
Leu	Arg	Val	Pro	Tyr	Ala	Lys	Pro	Pro	Ile	Gly	Asp	Leu	Arg	Trp	Leu	
65					70				75					80		
cct	cct	cat	cgg	ctt	gac	aac	tca	agc	aga	aca	tat	gac	tcc	acc	ttc	288
Pro	Pro	His	Arg	Leu	Asp	Asn	Ser	Ser	Arg	Thr	Tyr	Asp	Ser	Thr	Phe	
			85					90					95			
tat	ggc	cca	gcc	tgt	ccg	cag	tat	gtt	cca	gca	gag	agc	gat	ttt	tgg	336
Tyr	Gly	Pro	Ala	Cys	Pro	Gln	Tyr	Val	Pro	Ala	Glu	Ser	Asp	Phe	Trp	
			100					105					110			
aat	gaa	tat	gaa	ccg	gag	aat	ttg	ctg	ctc	aat	gtc	ggc	gaa	agg	ctc	384
Asn	Glu	Tyr	Glu	Pro	Glu	Asn	Leu	Leu	Leu	Asn	Val	Gly	Glu	Arg	Leu	
		115				120						125				
aac	cag	ggc	tct	acg	gca	tgg	tcc	tcg	tca	gag	gat	tgc	ctg	tcc	cta	432
Asn	Gln	Gly	Ser	Thr	Ala	Trp	Ser	Ser	Ser	Glu	Asp	Cys	Leu	Ser	Leu	
		130				135					140					
gcg	gta	tgg	act	cca	tcg	tat	gct	aat	gag	aca	tcc	aag	ctg	cca	gtt	480
Ala	Val	Trp	Thr	Pro	Ser	Tyr	Ala	Asn	Glu	Thr	Ser	Lys	Leu	Pro	Val	
145					150				155					160		
gcg	ctg	ttt	gtc	acg	gga	ggt	ggt	ggc	atc	aca	ggg	ggt	atc	aac	att	528
Ala	Leu	Phe	Val	Thr	Gly	Gly	Gly	Gly	Ile	Thr	Gly	Gly	Ile	Asn	Ile	
			165					170					175			
ccg	tcc	cag	ctg	ccc	tct	gct	tgg	gta	tct	cgc	tct	cag	gag	cat	atc	576
Pro	Ser	Gln	Leu	Pro	Ser	Ala	Trp	Val	Ser	Arg	Ser	Gln	Glu	His	Ile	
			180					185					190			

gtt gtt acc atc aat tac cgc gtc aat att ttt ggc aat ccc aaa tcg	624
Val Val Thr Ile Asn Tyr Arg Val Asn Ile Phe Gly Asn Pro Lys Ser	
195 200 205	
cgt gcg ttg aat gat acg tcg ctt acg ctg atg gac gtg cgc gct gct	672
Arg Ala Leu Asn Asp Thr Ser Leu Thr Leu Met Asp Val Arg Ala Ala	
210 215 220	
gtg gag tgg gta tat gag aac att gaa gcg ttc ggt ggt aat ccc gaa	720
Val Glu Trp Val Tyr Glu Asn Ile Glu Ala Phe Gly Gly Asn Pro Glu	
225 230 235 240	
aat att atg gtc aga cta caa gtt tcc tct cac atg act aga gct aac	768
Asn Ile Met Val Arg Leu Gln Val Ser Ser His Met Thr Arg Ala Asn	
245 250 255	
agt aag cag cta tgg gga cag tca caa ggt gct ttg ctg acg cat ctg	816
Ser Lys Gln Leu Trp Gly Gln Ser Gln Gly Ala Leu Leu Thr His Leu	
260 265 270	
tac acc ctc gca tgg cca gaa gag cct ctt gcc gcc aag ttc ggc gtc	864
Tyr Thr Leu Ala Trp Pro Glu Glu Pro Leu Ala Ala Lys Phe Gly Val	
275 280 285	
atc tcc caa gga gca tct gcc aca ctc aac ctc tct acc acg ccc gat	912
Ile Ser Gln Gly Ala Ser Ala Thr Leu Asn Leu Ser Thr Thr Pro Asp	
290 295 300	
gtg tac caa gac ttt gac atc gtg gcc aag gga cta ggc tgc aat tat	960
Val Tyr Gln Asp Phe Asp Ile Val Ala Lys Gly Leu Gly Cys Asn Tyr	
305 310 315 320	
ggt gat gat gcc gag gcc gag ctg gag tgc atg cgt ggg att tcc tgg	1008
Gly Asp Asp Ala Glu Ala Glu Leu Glu Cys Met Arg Gly Ile Ser Trp	
325 330 335	
gtg cag atc gag gag tat atc aac cgc tac aat agc tct cct tct att	1056
Val Gln Ile Glu Glu Tyr Ile Asn Arg Tyr Asn Ser Ser Pro Ser Ile	
340 345 350	
gct ttc acg aac tat att ccc gat gag aaa tac atc ttc tcc gac gaa	1104
Ala Phe Thr Asn Tyr Ile Pro Asp Glu Lys Tyr Ile Phe Ser Asp Glu	
355 360 365	
aga cag cgt tac ctt gag cgg aag gtt gcc cga ggc ccg tca att cga	1152
Arg Gln Arg Tyr Leu Glu Arg Lys Val Ala Arg Gly Pro Ser Ile Arg	
370 375 380	
tct gac acg gcg cga gaa ttc cct agc aca aac acg acc tca gta aat	1200
Ser Asp Thr Ala Arg Glu Phe Pro Ser Thr Asn Thr Thr Ser Val Asn	
385 390 395 400	
att gaa gaa ggc gaa tca gac tgt ctg gca gtg act gac ctt gcg cta	1248
Ile Glu Glu Gly Glu Ser Asp Cys Leu Ala Val Thr Asp Leu Ala Leu	
405 410 415	
cgt gcg tcc att ggg ctc gag acc tat cgc tac tac tgg gct ggc aac	1296
Arg Ala Ser Ile Gly Leu Glu Thr Tyr Arg Tyr Tyr Trp Ala Gly Asn	
420 425 430	
ttc tcc aat atc agt ccc gta ccg tgg cta gga gca ttc cac tgg acc	1344
Phe Ser Asn Ile Ser Pro Val Pro Trp Leu Gly Ala Phe His Trp Thr	
435 440 445	
gac ctg ctg atg atc ttc ggt acg tat aat ctg gac gtc ggc gag atc	1392
Asp Leu Leu Met Ile Phe Gly Thr Tyr Asn Leu Asp Val Gly Glu Ile	
450 455 460	
tcg cag ttg gaa gtc gac acc tct gcc acg atg caa gat tat cta ctc	1440
Ser Gln Leu Glu Val Asp Thr Ser Ala Thr Met Gln Asp Tyr Leu Leu	
465 470 475 480	
gcc ttt ctg aag gac tca tca acc gtc agc gag acg gtc gga tgg ccg	1488
Ala Phe Leu Lys Asp Ser Ser Thr Val Ser Glu Thr Val Gly Trp Pro	
485 490 495	

tta tat ctg ggc aac gag acc aac gga gga ctc atc ctg gag ttc ggt	1536
Leu Tyr Leu Gly Asn Glu Thr Asn Gly Gly Leu Ile Leu Glu Phe Gly	
500 505 510	
aac ggc aca gca gtg cgg acc atc aca ggt gac tgg ctc gac gcg gga	1584
Asn Gly Thr Ala Val Arg Thr Ile Thr Gly Asp Trp Leu Asp Ala Gly	
515 520 525	
tgt ttc aat tca tct atc cca ttc aga atc tgg ggg tag	1623
Cys Phe Asn Ser Ser Ile Pro Phe Arg Ile Trp Gly	
530 535 540	

<210> 3

<211> 540

<212> PRT

<213> Aspergillus niger

<400> 3

Met Val Gln Gly Val Ala Phe Gly Leu Leu Gly Leu Ala Ala Ser Ala	
1 5 10 15	
Leu Gly Thr Tyr Ala Pro Tyr Tyr Ala Asn Leu Thr Trp Glu Gln Pro	
20 25 30	
Arg Thr Leu Ser Asn Trp Ser Asn Leu Thr Val Glu Thr Arg Thr Gly	
35 40 45	
Thr Phe Ile Gly Met Leu Asn Asp Thr Tyr Pro Asp Val Arg Gln Phe	
50 55 60	
Leu Arg Val Pro Tyr Ala Lys Pro Pro Ile Gly Asp Leu Arg Trp Leu	
65 70 75 80	
Pro Pro His Arg Leu Asp Asn Ser Ser Arg Thr Tyr Asp Ser Thr Phe	
85 90 95	
Tyr Gly Pro Ala Cys Pro Gln Tyr Val Pro Ala Glu Ser Asp Phe Trp	
100 105 110	
Asn Glu Tyr Glu Pro Glu Asn Leu Leu Asn Val Gly Glu Arg Leu	
115 120 125	
Asn Gln Gly Ser Thr Ala Trp Ser Ser Ser Glu Asp Cys Leu Ser Leu	
130 135 140	
Ala Val Trp Thr Pro Ser Tyr Ala Asn Glu Thr Ser Lys Leu Pro Val	
145 150 155 160	
Ala Leu Phe Val Thr Gly Gly Gly Gly Ile Thr Gly Gly Ile Asn Ile	
165 170 175	
Pro Ser Gln Leu Pro Ser Ala Trp Val Ser Arg Ser Gln Glu His Ile	
180 185 190	
Val Val Thr Ile Asn Tyr Arg Val Asn Ile Phe Gly Asn Pro Lys Ser	
195 200 205	
Arg Ala Leu Asn Asp Thr Ser Leu Thr Leu Met Asp Val Arg Ala Ala	
210 215 220	
Val Glu Trp Val Tyr Glu Asn Ile Glu Ala Phe Gly Gly Asn Pro Glu	
225 230 235 240	
Asn Ile Met Val Arg Leu Gln Val Ser Ser His Met Thr Arg Ala Asn	
245 250 255	
Ser Lys Gln Leu Trp Gly Gln Ser Gln Gly Ala Leu Leu Thr His Leu	
260 265 270	
Tyr Thr Leu Ala Trp Pro Glu Glu Pro Leu Ala Ala Lys Phe Gly Val	
275 280 285	
Ile Ser Gln Gly Ala Ser Ala Thr Leu Asn Leu Ser Thr Thr Pro Asp	
290 295 300	
Val Tyr Gln Asp Phe Asp Ile Val Ala Lys Gly Leu Gly Cys Asn Tyr	
305 310 315 320	

Gly	Asp	Asp	Ala	Glu	Ala	Glu	Leu	Glu	Cys	Met	Arg	Gly	Ile	Ser	Trp
				325					330					335	
Val	Gln	Ile	Glu	Glu	Tyr	Ile	Asn	Arg	Tyr	Asn	Ser	Ser	Pro	Ser	Ile
			340					345					350		
Ala	Phe	Thr	Asn	Tyr	Ile	Pro	Asp	Glu	Lys	Tyr	Ile	Phe	Ser	Asp	Glu
		355					360					365			
Arg	Gln	Arg	Tyr	Leu	Glu	Arg	Lys	Val	Ala	Arg	Gly	Pro	Ser	Ile	Arg
	370				375						380				
Ser	Asp	Thr	Ala	Arg	Glu	Phe	Pro	Ser	Thr	Asn	Thr	Thr	Ser	Val	Asn
385					390					395					400
Ile	Glu	Glu	Gly	Glu	Ser	Asp	Cys	Leu	Ala	Val	Thr	Asp	Leu	Ala	Leu
			405					410						415	
Arg	Ala	Ser	Ile	Gly	Leu	Glu	Thr	Tyr	Arg	Tyr	Tyr	Trp	Ala	Gly	Asn
			420					425					430		
Phe	Ser	Asn	Ile	Ser	Pro	Val	Pro	Trp	Leu	Gly	Ala	Phe	His	Trp	Thr
		435					440					445			
Asp	Leu	Leu	Met	Ile	Phe	Gly	Thr	Tyr	Asn	Leu	Asp	Val	Gly	Glu	Ile
	450					455					460				
Ser	Gln	Leu	Glu	Val	Asp	Thr	Ser	Ala	Thr	Met	Gln	Asp	Tyr	Leu	Leu
465					470					475					480
Ala	Phe	Leu	Lys	Asp	Ser	Ser	Thr	Val	Ser	Glu	Thr	Val	Gly	Trp	Pro
			485					490						495	
Leu	Tyr	Leu	Gly	Asn	Glu	Thr	Asn	Gly	Gly	Leu	Ile	Leu	Glu	Phe	Gly
			500					505					510		
Asn	Gly	Thr	Ala	Val	Arg	Thr	Ile	Thr	Gly	Asp	Trp	Leu	Asp	Ala	Gly
		515					520					525			
Cys	Phe	Asn	Ser	Ser	Ile	Pro	Phe	Arg	Ile	Trp	Gly				
	530					535					540				